Carbapenem-Sparing Strategies for ESBL Producers: When and How

Carbapenem-Sparing Strategies for ESBL Producers: When and How

Extended spectrum β-lactamase (ESBL)-producing bacteria are prevalent worldwide and correlated with hospital infections, but they have been evolving as an increasing cause of community acquired infections. The spread of ESBL constitutes a major threat for public health, and infections with ESBL-prod...

Volledige beschrijving

Bewaard in:

Bibliografische gegevens
Hoofdauteurs:	Ilias Karaiskos, Helen Giamarellou
Formaat:	Revisão
Taal:	Engels
Gepubliceerd in:	2020
Online toegang:	https://doi.org/10.3390/antibiotics9020061 https://www.mdpi.com/2079-6382/9/2/61/pdf?version=1580901078
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Carbapenem-Sparing Strategies for ESBL Producers: When and How
door: Karaiskos, Ilias, et al.
Gepubliceerd in: (2020)

Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae
door: Helen Giamarellou, et al.
Gepubliceerd in: (2013)

Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae
door: Giamarellou, Helen, et al.
Gepubliceerd in: (2013)

Is Cefoxitin a Carbapenem Sparing Agent in the Management of Urinary Tract Infections Caused by ESBL Producing Enterobacterales?
door: El Nekidy, Wasim S., et al.
Gepubliceerd in: (2021)

Multidrug resistance in Gram-negative bacteria that produce extended-spectrum β-lactamases (ESBLs)
door: Helen Giamarellou
Gepubliceerd in: (2005)

Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance
door: Irene Galani, et al.
Gepubliceerd in: (2019)

Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance
door: Galani, Irene, et al.
Gepubliceerd in: (2019)

Correction to: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance
door: Galani, Irene, et al.
Gepubliceerd in: (2019)

Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches
door: Ilias Karaiskos, et al.
Gepubliceerd in: (2014)

Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients
door: Helen Giamarellou, et al.
Gepubliceerd in: (2022)

Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches
door: Karaiskos, Ilias, et al.
Gepubliceerd in: (2014)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
door: Takahiko Fukuchi, et al.
Gepubliceerd in: (2016)

Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
door: Fukuchi, Takahiko, et al.
Gepubliceerd in: (2016)

Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam
door: Irene Galani, et al.
Gepubliceerd in: (2019)

Activity of carbapenems and tigecycline against ESBL-producing Escherichia coli and Klebsiella spp.
door: Oliveira, Caio Fernando de, et al.
Gepubliceerd in: (2018)

To Use, or Not to Use Carbapenem When Extended-spectrum β-lactamase (ESBL)-producing Bacteria Are Isolated from Sputum Cultures, That Is the Question
door: Miki, Makoto
Gepubliceerd in: (2017)

Sparing carbapenem usage
door: A.P.R. Wilson
Gepubliceerd in: (2017)

Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs
door: Ilias Karaiskos, et al.
Gepubliceerd in: (2025)

1153. ESBL Producing E. coli Urinary Tract Infections in Children: Is Carbapenem Always Necessary?
door: del Carmen, Ruiz Cabrales Diva, et al.
Gepubliceerd in: (2021)

Antimicrobial Stewardship in the Hospital Setting: A Narrative Review
door: Helen Giamarellou, et al.
Gepubliceerd in: (2023)

The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
door: Ilias Karaiskos, et al.
Gepubliceerd in: (2019)

1452. Is Carbapenem-Sparing Therapy as Effective as Carbapenems Against Extended-Spectrum β-Lactamase Producing Enterobacteriaceae in UTI?
door: Hyun, Jonghoon, et al.
Gepubliceerd in: (2019)

1508. Carbapenem vs. Non-carbapenem as Empiric Regimens for Bacteremia Caused by ESBL Producing Escherichia coli and Klebsiella pneumoniae in Children: Preliminary Study
door: Park, Saera, et al.
Gepubliceerd in: (2019)

The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
door: Karaiskos, Ilias, et al.
Gepubliceerd in: (2019)

Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019
door: Galani, Irene, et al.
Gepubliceerd in: (2020)

Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates
door: C.-H. Lee, et al.
Gepubliceerd in: (2006)

Natural history and decolonization strategies for ESBL/carbapenem-resistant Enterobacteriaceae carriage: systematic review and meta-analysis
door: Haggai Bar‐Yoseph, et al.
Gepubliceerd in: (2016)

838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
door: Stone, Tyler J, et al.
Gepubliceerd in: (2020)

2442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems
door: John, Reeba, et al.
Gepubliceerd in: (2018)

479 Clinical outcomes in patients with extended-spectrum-beta-lactamase-producing (ESBL) Enterobacteriaceae bloodstream infections (ESB) treated with carbapenems (CP) and non-carbapenems (NC)
door: Chin, Judy, et al.
Gepubliceerd in: (2014)

Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae
door: Giusy Tiseo, et al.
Gepubliceerd in: (2024)

Distribution of carbapenem resistant Acinetobacter Baumannii and Pseudomonas aeruginosa and ESBL-producing organisms colonization among intensive care patients
door: Santanirand, P, et al.
Gepubliceerd in: (2011)

Screening for carbapenem-resistant Enterobacteriaceae: Who, When, and How?
door: Sandra S. Richter, et al.
Gepubliceerd in: (2016)

Screening for carbapenem-resistant Enterobacteriaceae: Who, When, and How?
door: Richter, Sandra S., et al.
Gepubliceerd in: (2016)

Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms
door: Marek Gniadkowski
Gepubliceerd in: (2001)

ESBL Activity, MDR, and Carbapenem Resistance among Predominant Enterobacterales Isolated in 2019
door: Bandy, Altaf, et al.
Gepubliceerd in: (2021)

Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis
door: Soo Kyung Son, et al.
Gepubliceerd in: (2018)

Moxalactam is not more active on extended spectrum β-lactamase (ESBL) producing bacteria than on non-ESBL producers
door: Singh, Bhoj R
Gepubliceerd in: (2018)

Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae: Results From the INCREMENT Cohort
door: Zaira R. Palacios‐Baena, et al.
Gepubliceerd in: (2017)

Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen
door: Martin Cormican, et al.
Gepubliceerd in: (1996)